On July 8, 2022, Suzhou RainMed Medical Technology Co., LTD. (Stock Code: 2297.HK, hereinafter referred to as "RainMed Medical") was officially listed on the main board of HKEX and held a bell ringing ceremony at 9:30 a.m.

RainMed Medical, founded in 2014, is committed to becoming world's leading vascular interventional robotics company. In the past 10 years, based on software and hardware development, medical image algorithm, CFD analysis, high-performance mechanical design, high-end interventional consumables research and development, RainMed Medical has developed a number of pioneering vascular diagnosis and treatment products, which has contributed a lot to world’s precise coronary diagnosis and treatment. 

After years of experience, RainMed Medical finally goes into a rapid development period. In 2021, RainMed’s revenue scale and gross margin growth rate exceeded 12 times, demonstrating its amazing marketing acceleration. According to statistics, in 2020 and 2021, the company achieved revenue of RMB 6.097 million and RMB 81.199 million respectively, with a growth rate of up to 1231.8%. While the income is growing rapidly, the profit performance of RainMed Medical also shows signs of accelerating improvement: in 2020 and 2021, the gross profit of RainMed Medical is 5.26 million yuan and 69.032 million yuan respectively, with a growth rate of 1212.4%, basically equal to the growth rate of income.

Currently, RainMed Medical takes the lead in developing the coronary angiography-derived Fractional Flow Reserve measurement system (caFFR System), coronary angiography-derived Index of Microcirculatory Resistance (caIMR System), and FlashBot Vascular intervention-surgery robot and two other products under development, which fill a number of market gaps and win the clinical and market recognition. As a leading national high-tech enterprise in the industry, RainMed Medical attaches great importance to scientific research and innovation, lays out rich product pipelines, and constantly opens up space for developing. The company continues to increase R&D investment, with an expenditure of 11.826 million yuan in 2020 and 26.97 million yuan in 2021. In the next two years, the caIMR system and the FlashBot coronary interventional robotic system are expected to be commercialized, injecting new vitality into the market.

caFFR System, the core product of digital functional diagnosis module of robot systems, has won the first prize in the hot FFR race with its excellent clinical performance and marketing level, becoming the first brand in domestic FFR field. caIMR, another core product of the module, also successfully completed its premarket clinical study, Flash III, with an ultra-high accuracy of 93.81%. As the world's first non-interventional IMR measurement product, the successful implementation of the pre-market clinical study of caIMR means that RainMed Medical may also lead the domestic IMR sector.

caFFR system and caIMR system are the core products of the digital functional module of the robot system. In the future, these two products will act as the "eyes" of the robot system and be integrated into FlashBot. FlashBot organically integrates functional diagnostic system, imaging surgical navigation, ECG monitoring and other software, as well as hardware such as interventional multifunctional catheter and high-pressure injection, forming multi-system function integration and data closed-loop, realizing the whole process of automatic angiography, diagnosis, navigation and postoperative evaluation. At present, FlashBot coronary artery interventional surgery robot has been developed and successfully entered the animal experiment stage.

"Nourish the Heart With Virtue, and Embark on the New Journey", the listing is not only an important milestone of RainMed Medical, but also a new starting point of the long journey. In the future, RainMed Medical will assume the responsibility and mission of a public company, uphold the original intention of "Targeted medical services for people's health", continue to deepen scientific research and innovation, explore the way of enterprise growth, and return the society and the majority of investors with excellent products and outstanding performance.